RYTM
Rhythm Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders +5.3% ·
aandelenstroom +5.1% ·
netto nieuwe posities 0.0%
— formule
Brede accumulatie — stijgende aandelen bij meer houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 112 | +7 | 44.38M | $4.90B | +14 | −8 |
| Q1 2026 | 109 | +6 | 41.83M | $3.64B | +11 | −6 |
| Q4 2025 | 102 | 0 | 43.14M | $4.62B | +3 | −2 |
| Q3 2025 | 20 | +1 | 28.88M | $2.92B | +2 | −2 |
| Q2 2025 | 17 | 0 | 22.96M | $1.45B | +1 | −1 |
| Q1 2025 | 14 | +2 | 11.52M | $610.22M | +2 | — |
| Q4 2024 | 12 | 0 | 11.40M | $638.39M | — | — |
| Q3 2024 | 11 | +3 | 9.71M | $508.75M | +3 | — |
| Q2 2024 | 8 | — | 9.56M | $392.54M | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 6.30M | +0.6% | $636.46M | 0.0% | ▲ Add | 2 | SEC ↗ ×16 |
| 2 | The Vanguard Group ✦ (passief) | 5.00M | +39.2% | $504.59M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | PRIMECAP Management ✦ | 4.26M | -12.6% | $430.51M | 0.3% | ▼ Trim | 6 | SEC ↗ |
| 4 | JPMorgan Chase ✦ | 2.38M | — | $239.97M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 5 | Fidelity (FMR) ✦ | 2.15M | +9.8% | $216.64M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 6 | State Street Global Advisors ✦ (passief) | 2.03M | +6.3% | $204.87M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Goldman Sachs Group ✦ | 1.89M | — | $191.24M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 8 | T. Rowe Price ✦ | 1.40M | +4.4% | $141.38M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Geode Capital Management ✦ (passief) | 1.36M | +3.9% | $137.65M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Renaissance Technologies ✦ | 546.59K | +73.6% | $55.20M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 11 | Adage Capital Partners ✦ | 544.00K | +59.5% | $54.94M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 12 | Morgan Stanley ✦ | 465.19K | — | $46.98M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 13 | Marshall Wace ✦ | 171.83K | -54.3% | $17.35M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Millennium Management ✦ | 133.16K | -32.8% | $13.45M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 132.63K | Nieuw | $13.39M | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 79.78K | +62.7% | $8.06M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 17 | Wellington Management ✦ | 24.48K | +9.2% | $2.47M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 18 | Arrowstreet Capital ✦ | 6.31K | Nieuw | $636,944 | 0.0% | New | 1 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 4.86K | +0.1% | $490,306 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 3.58K | -85.2% | $362,049 | 0.0% | ▼ Trim | 5 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Citadel Advisors | $13.39M | 0.0% |
| Arrowstreet Capital | $636,944 | 0.0% |
Verlaten
| Norges Bank | $13.10M | was 0.0% |
| Point72 Asset Management | $10.79M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 284 houders, 72.02M aandelen, $6.12B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director · 1.82K aand · $189,965
Officer, Director · 8.70K aand · $899,634
Officer, Director · 30.75K aand · $3.15M
Officer, Director · 6.44K aand · $655,145
Officer, Director · 2.30K aand · $241,937
Officer · 11.51K aand · $1.21M
Officer · 23.07K aand · $2.41M
Officer · 28.19K aand · $2.99M
Officer · 2.01K aand · $233,031
Officer · 1.56K aand · $182,170
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie